LKT Labs

Biochemicals for Life Science Research

Dabrafenib

Dabrafenib

Product ID D0004
Cas No. 1195765-45-7
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $75.00 In stock
25 mg $203.00 In stock
100 mg $721.00 In stock
Bulk Quote

Quicklinks

Description

Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.

Product Info

Cas No.

1195765-45-7
Purity

≥98%
Formula

C23H20F3N5O2S2
Formula Wt.

519.56
Chemical Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
IUPAC Name

N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1, 3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
Synonym

GSK2118436A
Solubility

soluble in DSMO
Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

D0004 MSDS PDF
Info Sheet

D0004 Info Sheet PDF
Brochures

Ras-Raf-MEK-ERK Pathway Booklet

References

Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. Drugs. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • L0400

    LB-100

    PP2A inhibitor.

    ≥98%
  • A985120

    AZD-0156

    Inhibitor of ATM.

    ≥98%
  • L0226

    Lagochiline

    Diterpene alkaloid found in Lagochilus.

    ≥98%
  • R3475

    Risperidone

    Benzisoxazole; 5-HT7 and NMDA agonist, D-amino ...

    ≥98%
  • D5690

    Doxazosin Mesylate

    Quinazoline; α1-adrenergic antagonist.

    ≥98%
  • T165131

    Tedizolid

    Effective against gram-positive pathogens

    ≥98%
  • C281006

    Chaetocin

    Chaetocin is naturally produced by Chaetomium s...

    ≥98%
  • T0153

    Tanshinone I

    Diterpene found in Salvia.

    ≥95%
  • C104762

    CCT-245737

    CHK1 inhibitor.

    ≥98%
  • E2542

    Met-Enkephalin Amide

    Endogenous opioid peptide; δOR and μOR agonis...

    ≥95%
  • C0167

    Carbenoxolone

    Synthetic glycyrrhetinic acid derivative; 11β-...

    ≥98%
  • S041001

    SB-202190

    Highly selective inhibitor

    ≥99%
  • E2002

    Efaroxan Hydrochloride

    α2-adrenergic and imidazoline-1 antagonist, AT...

    ≥99%
  • G062680

    GBR-12909 Dihydrochloride

    Dopamine reuptake inhibitor (DRI).

    ≥98%
  • C9200

    CX-6258

    Pim kinase inhibitor.

    ≥98%
  • P0255

    Pantoprazole

    H+/K+ ATPase and ROCK-2 inhibitor.

    ≥98%
  • E6245

    Eplerenone

    Mineralocorticoid antagonist.

    ≥99%
  • N0212

    Nedaplatin

    Pt-based DNA cross-linker.

    ≥98%
  • O486179

    Omeprazole Impurity C

    Impurity of omeprazole

    ≥99%
  • A0818

    15-Acetoxyscirpenol

    Trichothecene mycotoxin produced by Fusarium.

    ≥97%